Immunic CMO on CALLIPER MS trial results at ECTRIMS

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s presence at ECTRIMS - the world’s largest conference focused on multiple sclerosis research and treatment - including the oral presentation and the late-breaking poster on its phase 2 CALLIPER trial results of vidofludimus calcium in progressive multiple sclerosis (MS). Muehler explained that the CALLIPER trial demonstrated a medically relevant signal for prevention of disability progression in both primary progressive MS (PPMS) and non-active secondary progressive MS (SPMS) populations. He highlighted that unlike most approved therapies, the trial results were not driven by residual inflammatory activity, but instead pointed to a potential neuroprotective effect through Nurr1 activation. “CALLIPER really showed a medically relevant signal for disability … it was a very consistent signal in this trial,” he said. He added that vidofludimus calcium showed a 2.8 times increase in disability improvement events compared with placebo and maintained a strong safety and tolerability profile with no new safety signals. Beyond CALLIPER, Immunic also presented three additional posters, including phase 2 long-term extension data in relapsing-remitting MS, showing that more than 90% of patients remained free from disability worsening after over three years of treatment. The company also shared new preclinical findings that further support vidofludimus calcium’s neuroprotective mechanism. Looking ahead, Muehler said regulatory discussions for a potential phase 3 trial in progressive MS are ongoing, while the next major milestone will be from the fully enrolled ENSURE phase 3 trials in relapsing MS, which are expected to deliver results in 2026. For more videos, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and enable notifications for future updates. #Immunic #MultipleSclerosis #MSResearch #ECTRIMS2025 #ClinicalTrials #ProgressiveMS #RelapsingMS #VidofludimusCalcium #BiotechNews #Neuroprotection